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Abstract 
Background 
Novel Psychoactive Substance (NPS) use has increased in recent years and generated significant 
concern within public health. People who inject drugs (PWID) are at increased risk of blood borne 
viruses, in particular Hepatitis C virus (HCV). However, little is known about the extent of NPS 
injecting at a national level and its association with HCV. This study provides one of the first 
epidemiological analyses of the association between NPS injecting and HCV among a population 
level sample of PWID.  
Methods 
Five cross sectional surveys of almost 13,000 PWID attending services providing injecting equipment 
across Scotland between 2008 and 2016 were analysed. Logistic regression was used to determine 
associations between NPS injecting and HCV.  
Results 
The proportion of PWID reporting that they had injected NPS in the previous six months increased 
from 0.2% in 2008-09 to 11.0% in 2015-16. Those who reported injecting NPS were considerably 
more likely to be resident in the Lothian NHS Board area at the time of the study (AOR 5.6 (95% CI 
4.1–7.5)) and to have had recent experience of homelessness (AOR 1.4 (95% CI 1.0–1.9)). People 
who injected NPS were also significantly more likely to be HCV positive (AOR 1.7 (95% CI 1.2-2.4)). In 
Lothian, HCV prevalence rose from around 30% between 2008 and 2012 to 41% and then 48% in 
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2013-14 and 2015-16 respectively. Increases in prevalent HCV infection in Lothian may be partly 
attributed to increases in NPS injecting.  
Conclusion  
In Scotland, people who had injected Novel Psychoactive Substances were at increased risk of 
hepatitis C virus. Novel Psychoactive Substance injecting poses a threat to HCV elimination 
strategies. 
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Introduction 
The United Nations define Novel Psychoactive Substances (NPS) as “substances of abuse, either in a 
pure form or a preparation, that are not controlled by the 1961 Single Convention on Narcotic Drugs 
or the 1971 Convention on Psychotropic Substances, but which may pose a public health threat” 
(United Nations Office on Drugs and Crime, 2013). Although no universal categorisation exists, NPS 
can be generally classified within the following groups: stimulants, cannabinoids, hallucinogens, or 
depressants (Tracy et al, 2017). In response to growing concern about NPS use and related harms, 
the UK Psychoactive Substances Act came into force in 2016 which criminalised the production, 
supply, possession, importation and exportation of “any substance intended for human consumption 
that is capable of producing a psychoactive effect”.  
General population surveys internationally estimate past-year prevalence of NPS use between 0.4% 
and 5.9% (Khaled et al, 2016) but are likely to under-represent groups known to use NPS such as 
prisoners (Ralphs et al, 2017) and those with experience of homelessness (Smith et al, 2017). 
Moreover, evidence of NPS injecting among other vulnerable populations has emerged in recent 
years, in particular among current and former opioid users (Oprea et al, 2013; European Monitoring 
Centre for Drugs and Drug Addiction, 2017). In these examples, stimulant-type NPS injecting has 
typically been adopted as a substitute for, or complement to, traditional psychoactive drugs such as 
heroin.  
NPS use by people who inject drugs (PWID) is associated with high frequencies of injecting episodes 
and sharing of equipment (Karila et al, 2015) thus placing users at considerable risk of physical 
health harms including blood-borne viruses (BBV) (Tarján et al, 2015). Recent examples include an 
outbreak of HIV infection among NPS injectors in Dublin (Ireland) associated with frequency of 
injecting and homelessness (Giese et al, 2015), increases in BBV incidence among NPS injectors in 
Hungary associated with frequency of injecting, homelessness and low coverage of Injecting 
Equipment Provision (IEP) sites (Tarján et al, 2015; Rácz et al, 2016), and increased risk of 
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needle/syringe sharing and BBV infection among NPS injectors in England and Wales (Hope et al, 
2016).  
An outbreak of severe skin and soft tissue infections, bacteraemias and infective endocarditis among 
PWID was detected in the Lothian NHS Board area (henceforth ‘Lothian’) of Scotland in 2014 (Griffith 
et al, 2016; Yeung et al, 2017). Those most likely to be affected by this outbreak were former heroin 
injectors known to be injecting ethylphenidate, a stimulant-type NPS similar in chemical structure to 
methylphenidate and known to be associated with a high frequency of injecting (Lafferty et al, 
2016). The decision to adopt ethylphenidate as a drug of injection is complex, however it is likely to 
have been influenced by its availability in ‘head shops’ (shops traditionally associated with the sale 
of drug use paraphernalia) which are more prevalent in Lothian than in other parts of Scotland 
(Lafferty et al, 2016). Notably, Lothian also experienced a significant increase in prevalence of HCV in 
2015-16 despite traditionally having one of the lowest rates in Scotland (Health Protection Scotland 
et al, 2017). We hypothesised that this changing trend in HCV prevalence was associated with 
increases in NPS injecting in that locality.  
Using data from Scotland’s national surveillance system of infections and risks among PWID (Health 
Protection Scotland et al, 2017), this paper aims to: (i) to examine the prevalence of NPS injecting 
over time in Scotland among PWID and associated sociodemographic factors (ii) to assess the 
association between HCV and NPS injecting and (iii) examine NPS injecting with respect to HCV 
incidence.  
Materials and Methods 
Data sources 
The Needle Exchange Surveillance Initiative (NESI) is a voluntary, anonymous, cross-sectional survey 
of PWID, attending services providing injecting equipment, in mainland Scotland to monitor rates of 
BBV infection and risk behaviours in this population (Health Protection Scotland et al, 2017). During 
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2008-2016, five NESI surveys have been undertaken, each involving a sample of approximately 2,500 
PWID. Participants are asked to take part in a short survey and to give a dried blood spot sample to 
test anonymously for the presence of BBVs. A £5 shopping voucher is provided to individuals who 
complete the survey as compensation for their time. The interviews are carried out by trained 
interviewers who obtain informed consent from all participants prior to data collection.  Since NESI 
commenced, all dried blood spot samples have been tested for HCV antibodies. RNA testing has also 
been undertaken on antibody negative samples since 2008, principally to help identify incident 
(new) HCV infections.  More recently, routine RNA testing (of HCV antibody positives) has been 
introduced in NESI to monitor the impact of HCV treatment. NESI sampling and laboratory testing 
methods have been previously described in further detail (Health Protection Scotland et al, 2017). 
Ethical approval for the NESI survey was granted by the NHS West of Scotland Research Ethics 
Committee (REC Ref: 08/S0709/46). 
Setting 
Scotland has approximately 60,000 problem drug users (defined as those with problematic use of 
opioids and/or benzodiazepines) (NHS National Services Scotland, 2016), around 15000-20000 of 
which are estimated to be PWID (Hay et al, 2009; Overstall et al, 2014). The Lothian area of Scotland 
includes Edinburgh, the capital city of Scotland, and is estimated to have almost 10,000 problem 
drug users and around 3000 PWID.  
Outcomes 
In our first model, the outcome measure – NPS injecting – was derived from responses to NESI 
questions on drugs injected, specifically those answering Yes to whether they injected ‘Legal Highs’ 
(a common colloquialism for NPS in the UK) or not. Participants who named specific Legal Highs (e.g. 
mephedrone) within the ‘other’ section were also included following review. Prior to 2015-16, NPS 
injecting was identified in the ‘other’ field of drugs injected, however in 2015-16 a specific field for 
‘Legal Highs’ was added.  
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Those who provided a sufficient quality dried blood spot sample to be tested for HCV antibodies 
were included in our second model of HCV risk among NPS. The third model in our series also 
focussed on the HCV antibody dried blood spot result, specifically examining changes in the 
aggregate HCV positive rate over time among the population of PWID recruited in Lothian.  
Exposures of interest 
We assessed outcomes according to relevant sociodemographic and behavioural factors: age at time 
of survey; biological sex; NHS board of interview (Lothian, not in Lothian); recent homelessness (in 
the last six months, not in the last six months); recent history of heroin injecting (in the last six 
months, not in the last six months); prisoner status (never imprisoned, ever imprisoned); currently 
prescribed methadone (yes, no); injecting frequency (1-3 times per month, about once a week, 2 to 
6 times per week, once a day, 2 to 3 times per day, 4 or more times per day); recent needle sharing 
(in the last six months, not in the last six months) and needle re-use in the last six months (never, 
once or twice, 3 to 5 times, 5+ times).  
Analysis 
In total, 8878 PWID who had injected within the previous six months recruited as part of the 2008-
2016 NESI surveys were available for multivariate analysis following the removal of duplicate survey 
participants using basic identifiers (initials, gender, date of birth) and questionnaires with insufficient 
or missing demographic data. Where duplicates were identified, the survey with the first positive 
exposure to the outcome was selected (e.g. first reported NPS injecting or first positive HCV dried 
blood spot result). For those with no exposure to NPS and / or HCV infection, data from the first 
survey participation was included.  Unadjusted and adjusted logistic regression was then used to 
identify: (i) factors associated with NPS injecting and (ii) the association between HCV and NPS 
injecting. In the first model, data from all NESI surveys was pooled for analysis. For our second 
model, we focussed on data from 2068 individuals participating in the 2015-16 NESI survey given the 
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increase in NPS objecting observed at that time and the change in our survey methods to better 
identify NPS injecting.  
In our third model, we also used logistic regression to specifically examine NPS injecting with respect 
to HCV prevalence in 2015-16 among the population of PWID in Lothian. Here, the dependent 
variable was the aggregate HCV positivity rate for each survey and the covariates included were 
survey year and the percentage of PWID that reported injecting NPS in those years. Therefore, the 
model gives the average predicted HCV percentage for each NESI year and fits the binary dependent 
variable based on numbers of HCV positive and negative cases.  
Our final analysis explored recent [incident] HCV infection. In the very early stages of HCV infection, 
individuals have high levels of HCV virus (RNA) before developing antibodies; recent infections 
therefore refer to individuals who are HCV antibody negative and HCV RNA positive on dried blood 
spot testing. An estimate of HCV incidence can then be calculated using the formula: 
 
where T is the estimated duration of the window period, n is the number of recently acquired 
infections and N is the number of susceptibles (i.e. HCV antibody negatives) (Hope et al, 2011). An 
estimate of the duration of the window period (51 days) was derived from the literature (Page-
Shafer et al, 2008). 
All analyses were completed using R Statistical Software version 3.4.3. 
Results 
Participant characteristics  
Among the 8878 participants overall, 72% (n=6432) were male and 52% (n=4637) were aged under 
35 years (Table 1). A quarter (25%; n=2267) had experienced homelessness in the past six months 
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and just under two-thirds (61%; n=5412) had ever spent some time in prison.  The vast majority 
(94%; n=8373) had recently injected heroin and over two thirds were currently prescribed 
methadone (69%; n=6150).  
People who had injected NPS in the previous six months made up 3% (236/8878) of the sample in 
total, but the proportion of NPS injectors recruited per survey increased over time from 0.2% 
(5/2081) in 2008-09 to a high of 11.0% (186/1693) in 2015-16. Exclusive NPS use was rare and 
accounted for only 0.3% of the total sample (24/8878).  
In comparison to those who had not injected NPS, people who inject NPS were significantly more 
likely to be recruited from the Lothian region (accounting for over half of all NPS injectors) and to 
have been homeless within the past six months. Injecting risk behaviours were also more prevalent 
in those who had injected NPS including high frequency of injecting (four or more times per day), 
needle and syringe sharing and multiple re-use of needles (more than 5 times) in the past 6 months. 
In contrast, people who injected NPS were significantly less likely than non-NPS injectors to have 
also injected heroin in the past six months, however rates were still high at over 80%.  
INSERT TABLE 1 
Model 1: Factors associated with NPS injecting 
NPS injecting was most strongly associated with participation in more recent NESI surveys, in 
particular participation in 2015-16 when almost 80% of all NPS injectors were recruited in NESI 
(Table 2). In addition, those interviewed within Lothian were significantly more likely to report NPS 
injecting compared to those interviewed elsewhere. Odds of NPS injecting were also significantly 
higher for those who had recently experienced homelessness compared to those who had not  and 
those who had ever been in prison compared to those never incarcerated. In contrast, those 
injecting heroin in the previous six months were significantly less likely to be NPS injectors  
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compared to those who did not. Age was also negatively associated with each year increase in age 
significantly reducing the likelihood of being an NPS injector.  
In sensitivity analysis, we included an interaction effect between age and survey year (Table S1). The 
interaction coefficients in our model were not significant therefore it is unlikely that the strong 
association between NESI year and NPS injecting is dependent on age. 
INSERT TABLE 2 
Model 2: NPS injecting association with hepatitis C virus in Scotland 
In 2015-16, Individuals who reported injecting NPS were significantly more likely to be HCV positive 
compared to those who did not report NPS injecting (Table 3). This association remained significant 
in our adjusted model even after accounting for other known HCV risk and protective factors.  
INSERT TABLE 3 
In Scotland, HCV prevalence among active PWID (i.e. those who had injected in the previous six 
months) rose slightly between 2008 and 2016, from 52% to 58% (Figure 1). In Lothian, where 
prevalence of NPS injecting (29%) in NESI 2015-16 was highest in Scotland, HCV antibody prevalence 
rose from around 30% between 2008 and 2012 to 41% and then 48% in 2013-14 and 2015-16 
respectively.  This is particularly notable among recent onset injectors (i.e. those who commenced 
injecting in the past three years) where prevalence has almost doubled from 16% in 2008-09 to 30% 
in 2015-16. The increase in HCV prevalence in Lothian from 2011-12 onwards mirrors the onset of an 
increase in NPS injecting within the same locality.  
INSERT FIGURE 1 
Model 3: NPS injecting association with hepatitis C virus in Lothian 
In Lothian, unadjusted analysis associates NESI survey year with HCV prevalence (OR 1.14, 95% CI 
1.09-1.19) and NPS injecting prevalence with HCV prevalence (OR 1.03, 95% CI 1.02-1.03). However, 
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the effects of NESI survey year and NPS injecting prevalence diminish when taking into account 
prevalence of NPS in each survey. This suggests that increasing HCV prevalence in Lothian over time 
may be partly attributed to the parallel increase in NPS injecting, but as NPS injecting also loses 
statistical significance in the adjusted model, other factors that have not been considered in this 
model are also likely to be important.  (Table 4).  
INSERT TABLE 4 
Also in Lothian, the incidence of HCV in 2015-16 was 18.4 per 100 person years—on the basis of 
seven identified cases (antibody negative, PCR positive) of which three reported NPS injecting. 
Excluding Lothian, incidence of HCV in the rest of Scotland was 8.8 per 100 person years on the basis 
of 9 identified cases, none of which reported NPS injecting (data not shown).  
Increases in HCV prevalence and HCV incidence in Lothian, parallel to increases in reported NPS 
injecting, occurred at a time where other potential drivers of HCV infection have either remained 
relatively stable (e.g. shared needles/syringes in the last six months) or shown no similar trends (e.g. 
shared paraphernalia in the last six months) (Table 5).  
INSERT TABLE 5  
Discussion 
Infections associated with NPS injecting is an under-researched but important area of public health. 
This study adds to an emerging evidence base in this field by providing one of the first robust 
estimates of NPS injecting prevalence among a nationally representative sample of PWID and 
illuminating factors associated with a group at increased risk of BBV. Further, we also highlight the 
potential of NPS injecting clusters to reverse progress toward HCV elimination, a key target of the 
World Health Organisation (2016). 
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Homelessness as a risk factor for NPS injecting reflects findings from studies conducted in both 
Ireland (Giese et al, 2015) and Hungary (Tarján et al, 2015; Rácz et al, 2016). Homeless populations 
experience considerable health inequalities (Aldridge et al, 2018) and are amongst the hardest to 
reach in terms of both prevention and treatment. These challenges are compounded among 
individuals who are homeless and who also use drugs and prevalence of drug use in this population 
is known to be high (Fazel et al, 2006). Homelessness in the UK has been increasing since 2009 
(Public Health England, 2018), alongside increases in the availability of NPS over a similar period 
(European Monitoring Centre for Drugs and Drug Addiction, 2017), and at a time of declining heroin 
purity in the UK (Ahmad & Richardson, 2016).  These factors contribute to a high risk environment 
(Rhodes, 2009) of considerable public health concern. Efforts to reduce homelessness should be 
combined with efforts to prevent NPS use among homeless populations given the health risks 
studies such as ours and others have shown. For example, harm reduction services should consider 
how they re-orientate themselves to better accommodate NPS and/or homeless injectors e.g. by 
adopting more assertive outreach approaches such as street-based needle and syringe provision.  
Past prison experience as a risk factor for NPS use was not unexpected given the links established 
within previous studies (McAuley et al, 2015) and the high prevalence of PWID in prison populations 
(Blackman & Bradley, 2017). That said, the limited evidence base to date has focussed on synthetic 
cannabinoid use among prisoners (Blackman & Bradley, 2017; Ralphs et al, 2017), whilst our analysis 
exclusively focussed on PWID and therefore provides new insight on NPS injecting risk among former 
prisoners. Few people in our NESI surveys actually report injecting while incarcerated, therefore NPS 
injecting is likely to occur prior to admission, or following liberation. Despite this, prison should be 
viewed as an important setting for implementing NPS specific interventions aimed at reducing levels 
of harm.    
The association between NPS injecting and younger age has also been reported in Hungary (Tarján et 
al, 2015) and the rest of the UK (Hope et al, 2016) and is of particular concern given the progress in 
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reducing prevalence of injecting drug use in Scotland in recent years. Background epidemiology from 
needle and syringe exchange services (Health Protection Scotland et al, 2017), drug treatment 
services (NHS National Services Scotland, 2017a), drug-related hospital admissions (NHS National 
Services Scotland, 2017b) and drug-related deaths (National Records of Scotland, 2018) suggests 
that PWID in Scotland are an ageing cohort with fewer new injectors joining year on year. The 
increased risk of morbidity and mortality associated with injecting drug use is well established 
(Mathers et al, 2013), therefore any new threat to declining trends in injecting should be afforded 
the highest priority.  
Interesting findings regarding the relationship between NPS injecting and heroin injecting also 
emerged from our model, with heroin injectors less likely to also inject NPS. Despite this negative 
association, heroin injecting was considerably high amongst NPS injectors in our sample suggesting 
that exclusive NPS was uncommon. Such evidence reinforces the importance of effective opioid 
agonist therapy in potentially limiting the risk of drug users substituting one psychoactive substance 
for another in response to changes in drug markets.  
The significantly elevated risk of HCV among NPS injectors in Scotland mirrors the results from a 
similar study by Hope and colleagues (2016). Moreover, our new evidence challenges the advances 
made in recent years in reducing incidence of this infection through high coverage of harm reduction 
interventions (Palmateer et al, 2014). Although we were unable to attribute increases in incidence of 
HCV infection in Scotland specifically to NPS due to a lack of statistical power, it is notable that the 
area with the highest prevalence of NPS injecting in Scotland, Lothian, observed one of the highest 
absolute (7%) and relative (17%) increases in HCV prevalence between 2013-14 and 2015-16. This 
was despite attendances at IEP services in Lothian increasing during the same period (NHS National 
Services Scotland, 2017c). The rate of new infections in this locality (18.4 per 100 person years) was 
also markedly higher compared to the rest of Scotland in 2015-16 (9.2 per 100 person years). If NPS 
injecting is a key factor behind such increases, as it has been in Hungary (Tarján et al, 2015), then it 
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poses a major threat to the call by the World Health Organisation Global Health Sector Strategy on 
viral hepatitis to reduce newly acquired chronic HCV infections by 30% by 2020 and 90% by 2030 
(World Health Organisation, 2016). Regular testing is a key component of HCV prevention through 
identification of new cases, linkage to treatment and care and providing opportunities for awareness 
raising regarding risk behaviours. Future research should determine the extent to which NPS 
injectors have been tested and treated for HCV given the highly effective therapies now available in 
the Direct Acting Antiviral (DAA) era.  
As the first multivariate analysis of NPS injecting and related harms among a nationally 
representative sample of PWID, this study has important implications for policy and practice. 
Primarily it will be of interest to policymakers focussed on reducing harms associated with drug use 
and achieving realistic public health goals such as HCV elimination. NPS injecting threatens both 
these targets. Internationally, robust population level studies such as these are important in 
highlighting and quantifying the impact of NPS injecting within different countries to allow strategies 
to be developed prospectively to mitigate similar impacts elsewhere. Lessons from Scotland 
highlight that high harm reduction coverage is not sufficient on its own to prevent negative impacts 
associated with NPS injecting. However, given a lack of evidence on the effectiveness of 
interventions to address NPS-related harm, approaches that are known to reduce injecting related 
harms (i.e. IEP and BBV testing and treatment) should be modified for NPS users (European 
Monitoring Centre for Drugs and Drug Addiction, 2016). This includes adapting content of existing 
interventions, enhancing their delivery in settings where NPS users are likely to be accessible, and 
ensuring staff (and peers where appropriate) are adequately trained to deliver them. Legislative 
changes to specific NPS have been effective at reducing harms in the past within an outbreak 
situation (Yeung et al, 2017). It remains to be seen whether more universal approaches, such as the 
recent UK Psychoactive Substances Act, will have a similar positive effect. A comparable blanket ban 
in Ireland, implemented in 2010, has yet to be systematically evaluated (Reuter & Pardo, 2017).  
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We acknowledge a number of limitations with this study. Firstly, the inclusion of an NPS specific 
question in the survey in 2015-16 may partly explain the increase in NPS use we observed. However, 
numerous other sources (Griffith et al, 2016; Lafferty et al, 2016; Yeung et al, 2017; Pettie et al, 
2018) have also confirmed a rise in NPS injecting in Lothian at this time therefore we are reassured 
that the increase we observed in our data is reflective of the actual trend occurring at the time. 
Similarly, it became clear during the course of the outbreak that heroin available in Lothian had been 
mixed with ethylphenidate, therefore increasing the possibility that individuals were injecting NPS 
unknowingly (Yeung et al, 2017). This also may have underestimated rates of NPS use, therefore our 
model estimates should be viewed as conservative which is perhaps even more concerning in public 
health terms.  Secondly, our primary outcome measure, NPS injecting, is derived from self-reported 
responses which may be subject to response bias despite our use of independent researchers. The 
reliability of self-report to describe drug use behaviours has previously been validated (Darke, 1998) 
and we assume similar validity applied to the responses in this study. The comparability of our 
findings to the limited number of studies conducted in this area thus far provided reassurance 
regarding this assumption. Lastly, our sample is biased towards those attending sites providing IEP 
and therefore under represents PWID who do not regularly engage with such services. Despite this, 
use of IEP among PWID in Scotland is typically high and the 2015-16 NESI survey covered 118 IEP 
sites across all of mainland Scotland (relating to approximately 63% of all sites across the country) 
(NHS National Services Scotland, 2017c) therefore we are confident that the sample is nationally 
representative. 
Conclusion  
The phenomenal growth in the availability and use of NPS internationally has presented a key 
challenge for public health in recent years. The lack of evidence on the drugs themselves, and harms 
associated with their use, has hindered policymakers and practitioners in their responses. Our study 
has shown that people who inject NPS in Scotland are at increased risk of HCV, despite high 
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coverage of harm reduction interventions. This increased risk appears to have reversed previously 
stable trends in HCV prevalence in a locality where NPS injecting took hold quickly and substantially. 
Prevention efforts should optimise harm reduction approaches, with a particular focus on homeless 
and ex-prisoner populations who appear particularly vulnerable to NPS injecting and related harms.    
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Table 1: Characteristics of people who inject drugs (PWID) in Scotland participating in the Needle Exchange Surveillance Initiative, overall and for those who 
had reported injecting NPS, 2008-2016   
    PWID Excluding NPS users % People who inject NPS % pa 
  
8642 
 
236 
 
 
 
People who injected NPS only 0 0.0 24 10.2  
NESI Year 2008-12 2076 24.0 5 2.1  
  2010 2106 24.4 0 0.0  
  2011-12 1434 16.6 1 0.4  
  2013-14 1519 17.6 44 18.6  
  2015-16 1507 17.4 186 78.8  
Region of Scotland Rest of Scotland 7515 87.0 116 49.2 <0.001 
  Lothian 1127 13.0 120 50.8 <0.001 
Gender Female 2336 27.0 61 25.8 0.742 
  Male 6259 72.4 173 73.3 0.822 
  Other/Unknown 47 0.5 2 0.8 0.860 
Age Group <35 years 4505 52.1 132 55.9 0.277 
  35 years + 4126 47.7 102 43.2 0.191 
  Unknown/Missing 11 0.1 2 0.8 0.046 
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Ever Been in Prison No 3359 38.9 81 34.3 0.178 
  Yes 5259 60.9 153 64.8 0.243 
  Unknown/Missing 24 0.3 2 0.8 0.323 
Homeless in the Last 6 Months No 6434 74.5 153 64.8 0.001 
  Yes 2186 25.3 81 34.3 0.002 
  Unknown/Missing 22 0.3 2 0.8 0.273 
Currently on Methadone No 2640 30.5 85 36.0 0.084 
  Yes 5999 69.4 151 64.0 0.087 
  Unknown/Missing 3 0.0 0 0.0 1.000 
Injected Heroin in the Last 6 Months No 459 5.3 43 18.2 <0.001 
  Yes 8180 94.7 193 81.8 <0.001 
  Unknown/Missing 3 0.0 0 0.0 1.000 
Average Injecting Frequency in the Last 6 Months Less than daily 4039 46.7 78 33.1 <0.001 
  1 to 3 times a day 3729 43.1 108 45.8 0.464 
  4 or more times a day 868 10.0 49 20.8 <0.001 
  Unknown/Missing 6 0.1 1 0.4 0.461 
Shared Needles in the Last 6 Months No 7733 89.5 198 83.9 0.008 
  Yes 854 9.9 35 14.8 0.017 
{ PAGE   \* MERGEFORMAT } 
 
  Unknown/Missing 55 0.6 3 1.3 0.433 
Average Needle Reuse in the Last 6 Months Never 3897 45.1 79 33.5 <0.001 
  Once or twice 2757 31.9 66 28.0 0.226 
  3 to 5 times 1087 12.6 39 16.5 0.089 
  5+ times 847 9.8 50 21.2 <0.001 
  Unknown/Missing 54 0.6 2 0.8 0.992 
HCV Antibody Result No 3964 45.9 83 35.2 0.001 
 
Yes 4539 52.5 147 62.3 0.004 
 
Unknown/Missing 139 1.6 6 2.5 0.392 
 
a Chi-square test for association 
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Table 2: Factors associated with NPS injecting among 8767 PWID reporting injecting in the previous 
six months, Scotland, 2008-2016 
NPS injectors, 228/8767 (2.6%) 
 OR (95% CI) p AOR (95% CI) p 
Age (Per Year Increase) 1.00 (0.98–1.02) 0.847 0.95 (0.93–0.97) <0.001 
NESI Year      
    2008-09, 2010, 2011-12 1.00  1.00  
    2013-14 27.11 (11.53–63.74) <0.001 26.06 (10.99–61.78) <0.001 
    2015-16 115.52 (51.14–
260.96) 
<0.001 120.65 (52.91–
275.11) 
<0.001 
Gender     
    Female 1.00  1.00  
    Male 1.06 (0.79–1.42) 0.706 0.92 (0.65–1.29) 0.623 
Region of Scotland     
    Rest of Scotland 1.00  1.00  
    Lothian NHS Board 6.90 (5.30–8.97) <0.001 5.57 (4.14–7.49) <0.001 
Homeless in the Last 6 Months     
    No 1.00  1.00  
    Yes 1.56 (1.19–2.05) 0.001 1.42 (1.04–1.94) 0.030 
Injected Heroin in the Last 6 
Months 
    
    No 1.00  1.00  
    Yes 0.25 (0.18–0.36) <0.001 0.30 (0.20–0.46) <0.001 
Ever Been in Prison     
    No 1.00  1.00  
    Yes 1.21 (0.92–1.58) 0.177 1.60 (1.16–2.22) 0.005 
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Table 3: Factors associated with HCV antibody infection among 2068 PWID reporting injecting in the previous six months, Scotland, 2015-16 
HCV positive, 1201/2068 (58%)     
  OR (95% CI) p AOR (95% CI) p 
Injected NPS in the Last 6 Months 
    
    No 1.00 
 
1.00 
 
    Yes 1.40 (1.05–1.87) 0.023 1.71 (1.23–2.38) 0.001 
Region of Scotland 
    
    Rest of Scotland 1.00 
 
1.00 
 
    Lothian 0.61 (0.49–0.75) <0.001 0.48 (0.38–0.62) <0.001 
Age (Per Year Increase) 1.06 (1.04–1.07) <0.001 1.06 (1.05–1.08) <0.001 
Gender 
    
    Female 1.00 
 
1.00 
 
    Male 1.01 (0.83–1.23) 0.897 0.89 (0.72–1.10) 0.297 
Homeless in the Last 6 Months 
    
    No 1.00 
 
1.00 
 
    Yes 1.49 (1.21–1.84) <0.001 1.66 (1.32–2.08) <0.001 
Currently on Methadone 
    
    No 1.00 
 
1.00 
 
    Yes 1.43 (1.17–1.73) <0.001 1.36 (1.10–1.68) 0.005 
Average Injecting Frequency in the Last 6 Months 
    
    Less than daily 1.00 
 
1.00 
 
    1 to 3 times a day 1.24 (1.04–1.49) 0.017 1.15 (0.94–1.39) 0.166 
    4 or more times a day 2.23 (1.58–3.14) <0.001 2.39 (1.63–3.50) <0.001 
Shared Needles/Syringes in the Last 6 Months 
    
    No 1.00 
 
1.00 
 
    Yes 1.45 (1.02–2.06) 0.041 1.39 (0.94–2.06) 0.095 
Average Needle Reuse in the Last 6 Months 
    
    Never 1.00 
 
1.00 
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    Once or twice 1.37 (1.11–1.69) 0.003 1.33 (1.06–1.66) 0.012 
    3 to 5 times 1.47 (1.11–1.93) 0.006 1.36 (1.01–1.82) 0.044 
    5+ times 1.44 (1.10–1.88) 0.008 1.31 (0.98–1.76) 0.071 
Used Contraception in the Last 6 Months 
    
    Yes 1.00 
 
1.00 
 
    No 1.30 (1.07–1.59) 0.008 1.13 (0.91–1.40) 0.267 
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Table 4: Factors associated with aggregate HCV antibody prevalence among PWID reporting injecting 
in the previous six months, Lothian NHS Board, 2008-2016 
  OR 95% CI p AOR 95% CI p 
NESI Year 1.14 1.09 – 1.19 <0.01 1.07 0.97 – 1.19 0.19 
% NPS injectors 1.03 1.02 – 1.03 <0.01 1.01 0.99 – 1.03 0.21 
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Table 5: Trends in demographics, OST engagement and injecting risk behaviours among PWID in Lothian NHS Board, 2008-2016 
    NESI year 
    2008-09 2010 2011-12 2013-14 2015-16 
Number recently infected*   1 3 2 0 7 
HCV incidence   per 100 person-years 3.4 8.2 7.3 n/a 18.4 
  95% CI 0.0, 11.3 0.0, 18.0 0.0, 18.1  n/a 6.8, 31.1 
Mean (SD) Age mean 32.6 32.9 34.1 34.8 37.1 
  SD 7.2 7.1 7.1 7.8 7.6 
Male n 202 254 157 184 324 
  % within NESI year 76.2% 77.7% 77.3% 74.8% 75.7% 
Homeless in the last six months n 88 94 45 89 151 
  % within NESI year 33.2% 28.7% 22.2% 36.2% 35.3% 
Currently on methadone n 170 236 123 142 241 
  % within NESI year 75.2% 81.1% 73.7% 69.3% 64.1% 
Injected Heroin in the last six months n 257 322 194 223 386 
  % within NESI year 97.0% 98.5% 95.6% 90.7% 90.2% 
Ever been in prison n 141 174 102 141 240 
  % within NESI year 53.2% 53.5% 50.2% 57.6% 56.5% 
Shared Needles/Syringes in the last six months n 24 36 22 23 42 
  % within NESI year 9.1% 11.0% 10.8% 9.3% 9.8% 
Shared paraphernalia in the last six months n 107 129 67 57 122 
  % within NESI year 40.4% 39.4% 33.0% 23.2% 28.5% 
Reused Needles/Syringes 5+ times, on average, in the last six 
months 
n 10 51 42 42 84 
% within NESI year 3.8% 15.6% 20.7% 17.1% 19.6% 
 
*In the very early stages of HCV infection, individuals have high levels of HCV virus (RNA) before developing antibodies (anti-HCV); recent infections therefore refer to individuals who are anti-HCV negative and HCV 
RNA positive 
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FIGURE 1: HCV prevalence and NPS injecting prevalence, Scotland and Lothian NHS Board, 2008-
2016 
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